Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

NCT06006013 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Adrenal Cortex Carcinoma
Adrenal Cortical Carcinoma
Stage III Adrenal Cortex Carcinoma
Stage IV Adrenal Cortex Carcinoma AJCC v8
Unresectable Adrenal Cortex Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
PROCEDURE: Biospecimen Collection
DRUG: Cabozantinib S-malate
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging

Sponsor

Emory University

Collaborators

National Cancer Institute (NCI)